Corbus Pharmaceuticals (CRBP) to Release Earnings on Thursday

Share on StockTwits

Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its earnings data before the market opens on Thursday, November 8th. Analysts expect Corbus Pharmaceuticals to post earnings of ($0.21) per share for the quarter.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The company had revenue of $0.85 million during the quarter, compared to the consensus estimate of $1.90 million. On average, analysts expect Corbus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ CRBP traded up $0.09 during trading on Tuesday, reaching $7.25. The company had a trading volume of 32,828 shares, compared to its average volume of 1,143,557. Corbus Pharmaceuticals has a 12 month low of $4.50 and a 12 month high of $9.95. The firm has a market capitalization of $416.46 million, a PE ratio of -11.11 and a beta of 2.16.

A number of research firms have commented on CRBP. Cantor Fitzgerald set a $36.00 price target on Corbus Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, September 13th. ValuEngine upgraded Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 18th. Finally, BidaskClub upgraded Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $25.50.

WARNING: “Corbus Pharmaceuticals (CRBP) to Release Earnings on Thursday” was first reported by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

Featured Article: Why do companies issue stock splits?

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply